GSA Capital Partners LLP Buys New Stake in Ocugen, Inc. (NASDAQ:OCGN)

GSA Capital Partners LLP purchased a new position in shares of Ocugen, Inc. (NASDAQ:OCGN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 204,310 shares of the company’s stock, valued at approximately $203,000. GSA Capital Partners LLP owned 0.07% of Ocugen as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in OCGN. Bank of New York Mellon Corp lifted its position in shares of Ocugen by 2,760.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 751,819 shares of the company’s stock worth $1,165,000 after buying an additional 725,536 shares during the period. Rhumbline Advisers lifted its holdings in shares of Ocugen by 3,040.0% during the second quarter. Rhumbline Advisers now owns 301,218 shares of the company’s stock valued at $467,000 after acquiring an additional 291,625 shares during the period. Profund Advisors LLC acquired a new stake in shares of Ocugen in the 2nd quarter valued at $227,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Ocugen in the 2nd quarter valued at $166,000. Finally, NorthCrest Asset Manangement LLC bought a new stake in shares of Ocugen in the 3rd quarter worth about $90,000. 10.27% of the stock is owned by institutional investors and hedge funds.

Ocugen Stock Up 0.7 %

Shares of NASDAQ OCGN opened at $0.91 on Monday. Ocugen, Inc. has a 12-month low of $0.36 and a 12-month high of $2.11. The firm’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.32. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The company has a market cap of $264.34 million, a price-to-earnings ratio of -5.04 and a beta of 3.75.

Analyst Ratings Changes

OCGN has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Ocugen in a report on Monday, November 11th. Maxim Group began coverage on shares of Ocugen in a research note on Tuesday, October 15th. They issued a “buy” rating and a $4.00 target price for the company. Finally, Chardan Capital restated a “buy” rating and set a $6.00 price target on shares of Ocugen in a research report on Monday, November 18th.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.